Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070243 | 0.85 | HCRTR1 (0.47) | HCRTR1HCRTR2CCR1CCR5CCR8 | |
| SCHEMBL20070247 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2CCR1CCR5CCR8 | |
| SCHEMBL17448852 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2CCR1CCR5CCR8 | |
| SCHEMBL28664238 | 0.77 | ROCK1 (0.49) | HCRTR1HCRTR2CCR1CCR5CCR8 | |
| SCHEMBL20147967 | 0.76 | MCHR1 (0.40) | RETALDH1A1GAAKMT2A | |
| SCHEMBL20147435 | 0.76 | HRH3 (0.52) | HCRTR1HCRTR2CCR1CCR5CCR8 | |
| SCHEMBL24188502 | 0.74 | AXL (0.39) | — | |
| SCHEMBL2760245 | 0.73 | PDE3B (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL1206676 | 0.73 | CCR1 (0.64) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL20069137 | 0.73 | CHRNB2 (0.38) | ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HCRTR1 2257/4885HCRTR2 3543/4885CCR1 1283/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HCRTR1 2257/4885HCRTR2 3543/4885CCR1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.